Lakefront Biotherapeutics NV current report, Q3 FY2015

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer, for the month of August 2015. The filing, dated August 6, 2015, serves as a report pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The registrant is based in Mechelen, Belgium, and files annual reports under Form 20-F.

Financial Metrics

The provided filing text is a cover sheet and does not contain specific financial data. It references the "Galapagos NV Half-year Report 2015" as Exhibit 99.2, but the text of that report is not included in the input. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not available in this document.

Material Changes

The filing text does not provide details on material changes versus prior periods. It lists three exhibits: a press release dated August 5, 2015; the Half-year Report 2015; and a press release dated August 6, 2015. The content of these exhibits is not summarized in the provided text.

Guidance, Outlook, and Risks

Management commentary, guidance, outlook, risks, contingencies, and unusual items are not described in the cover sheet text. The filing indicates that the Chief Financial Officer, Bart Filius, authorized the report.

Key Facts for Investor Verification

  • Verify the contents of Exhibit 99.2 (Half-year Report 2015) for actual financial performance data.
  • Review the press releases in Exhibits 99.1 and 99.3 for specific corporate developments or announcements made on August 5 and August 6, 2015.
  • Confirm the company's status as a foreign private issuer filing under Form 20-F.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.